# Protara Therapeutics, Inc.: financial statements, quarterly

TARA · Nasdaq · CIK 1359931 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tara.md) · [Financials](/companies/tara/financials.md) · [Filings](/companies/tara/filings.md) · [Insiders](/companies/tara/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tara/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [6.2](/filings/0001213900-24-096252.md) | [6.4 d](/filings/0001213900-25-020368.md) | [7.7](/filings/0001213900-25-040811.md) | [6.4](/filings/0001213900-25-073942.md) | [8.1](/filings/0001213900-25-107881.md) | [9.5 d](/filings/0001213900-26-025433.md) | [9.1](/filings/0001213900-26-055463.md) | [10.8](/filings/0001213900-26-087508.md) | [9.6](/filings/0001213900-25-107881.md) | [13.1 d](/filings/0001213900-26-025433.md) | [13.6](/filings/0001213900-26-055463.md) | [17.0](/filings/0001213900-26-087508.md) |
| Operating income | $m | [(10.7)](/filings/0001213900-24-096252.md) | [(11.0) d](/filings/0001213900-25-020368.md) | [(11.9)](/filings/0001213900-25-040811.md) | [(10.7)](/filings/0001213900-25-073942.md) | [(12.3)](/filings/0001213900-25-107881.md) | [(14.3) d](/filings/0001213900-26-025433.md) | [(14.1)](/filings/0001213900-26-055463.md) | [(16.6)](/filings/0001213900-26-087508.md) | [(14.8)](/filings/0001213900-25-107881.md) | [(19.1) d](/filings/0001213900-26-025433.md) | [(19.6)](/filings/0001213900-26-055463.md) | [(23.3)](/filings/0001213900-26-087508.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.9)](/filings/0001213900-24-096252.md) | [(10.2) d](/filings/0001213900-25-020368.md) | [(11.1)](/filings/0001213900-25-107881.md) | [(9.5)](/filings/0001213900-25-107881.md) | [(11.2)](/filings/0001213900-25-107881.md) | [(12.8) d](/filings/0001213900-26-025433.md) | [(11.9)](/filings/0001213900-26-087508.md) | [(15.0)](/filings/0001213900-26-087508.md) | [(13.3)](/filings/0001213900-25-107881.md) | [(17.3) d](/filings/0001213900-26-025433.md) | [(17.8)](/filings/0001213900-26-087508.md) | [(21.7)](/filings/0001213900-26-087508.md) |
| Diluted EPS | $ per share | [(0.87)](/filings/0001213900-24-096252.md) | not reported | [(0.97)](/filings/0001213900-25-040811.md) | [(0.45)](/filings/0001213900-25-073942.md) | [(0.50)](/filings/0001213900-25-107881.md) | not reported | [(0.29)](/filings/0001213900-26-055463.md) | [(0.35)](/filings/0001213900-26-087508.md) | [(0.31)](/filings/0001213900-25-107881.md) | not reported | [(0.31)](/filings/0001213900-26-055463.md) | [(0.36)](/filings/0001213900-26-087508.md) |
| Basic EPS | $ per share | [(0.87)](/filings/0001213900-24-096252.md) | not reported | [(0.97)](/filings/0001213900-25-040811.md) | [(0.45)](/filings/0001213900-25-073942.md) | [(0.50)](/filings/0001213900-25-107881.md) | not reported | [(0.29)](/filings/0001213900-26-055463.md) | [(0.35)](/filings/0001213900-26-087508.md) | [(0.31)](/filings/0001213900-25-107881.md) | not reported | [(0.31)](/filings/0001213900-26-055463.md) | [(0.36)](/filings/0001213900-26-087508.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.8](/filings/0001213900-23-083013.md) | [39.6](/filings/0001213900-25-020368.md) | [52.2](/filings/0001213900-24-038757.md) | [89.6](/filings/0001213900-24-065380.md) | [51.8](/filings/0001213900-24-096252.md) | [163](/filings/0001213900-26-025433.md) | [91.5](/filings/0001213900-25-040811.md) | [31.5](/filings/0001213900-25-073942.md) | [12.6](/filings/0001213900-25-107881.md) | [49.7](/filings/0001213900-26-087508.md) | [14.7](/filings/0001213900-26-055463.md) | [17.1](/filings/0001213900-26-087508.md) |
| Current assets | $m | [77.8](/filings/0001213900-23-083013.md) | [68.7](/filings/0001213900-25-020368.md) | [57.9](/filings/0001213900-24-038757.md) | [92.2](/filings/0001213900-24-065380.md) | [85.1](/filings/0001213900-24-096252.md) | [172](/filings/0001213900-26-025433.md) | [127](/filings/0001213900-25-040811.md) | [125](/filings/0001213900-25-073942.md) | [136](/filings/0001213900-25-107881.md) | [160](/filings/0001213900-26-087508.md) | [140](/filings/0001213900-26-055463.md) | [146](/filings/0001213900-26-087508.md) |
| Total assets | $m | [88.5](/filings/0001213900-23-083013.md) | [79.0](/filings/0001213900-25-020368.md) | [68.1](/filings/0001213900-24-038757.md) | [102](/filings/0001213900-24-065380.md) | [94.1](/filings/0001213900-24-096252.md) | [181](/filings/0001213900-26-025433.md) | [169](/filings/0001213900-25-040811.md) | [157](/filings/0001213900-25-073942.md) | [145](/filings/0001213900-25-107881.md) | [209](/filings/0001213900-26-087508.md) | [192](/filings/0001213900-26-055463.md) | [176](/filings/0001213900-26-087508.md) |
| Current liabilities | $m | [6.8](/filings/0001213900-23-083013.md) | [6.1](/filings/0001213900-25-020368.md) | [5.5](/filings/0001213900-24-038757.md) | [5.6](/filings/0001213900-24-065380.md) | [8.6](/filings/0001213900-24-096252.md) | [11.0](/filings/0001213900-26-025433.md) | [7.0](/filings/0001213900-25-040811.md) | [9.8](/filings/0001213900-25-073942.md) | [9.9](/filings/0001213900-25-107881.md) | [10.9](/filings/0001213900-26-087508.md) | [8.9](/filings/0001213900-26-055463.md) | [13.3](/filings/0001213900-26-087508.md) |
| Total liabilities | $m | [11.5](/filings/0001213900-23-083013.md) | [10.6](/filings/0001213900-25-020368.md) | [9.7](/filings/0001213900-24-038757.md) | [9.6](/filings/0001213900-24-065380.md) | [12.3](/filings/0001213900-24-096252.md) | [14.3](/filings/0001213900-26-025433.md) | [10.1](/filings/0001213900-25-040811.md) | [12.5](/filings/0001213900-25-073942.md) | [12.3](/filings/0001213900-25-107881.md) | [13.1](/filings/0001213900-26-087508.md) | [10.7](/filings/0001213900-26-055463.md) | [14.8](/filings/0001213900-26-087508.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [77.0](/filings/0001213900-24-096252.md) | [68.3](/filings/0001213900-26-025433.md) | [58.4](/filings/0001213900-25-107881.md) | [92.1](/filings/0001213900-25-107881.md) | [81.8](/filings/0001213900-25-107881.md) | [167](/filings/0001213900-26-087508.md) | [158](/filings/0001213900-26-087508.md) | [144](/filings/0001213900-26-087508.md) | [132](/filings/0001213900-25-107881.md) | [196](/filings/0001213900-26-087508.md) | [181](/filings/0001213900-26-087508.md) | [161](/filings/0001213900-26-087508.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.6) d](/filings/0001213900-24-096252.md) | [(8.7) d](/filings/0001213900-25-020368.md) | [(10.4)](/filings/0001213900-25-040811.md) | [(7.7) d](/filings/0001213900-25-073942.md) | [(8.4) d](/filings/0001213900-25-107881.md) | [(9.3) d](/filings/0001213900-26-025433.md) | [(14.7)](/filings/0001213900-26-055463.md) | [(12.3) d](/filings/0001213900-26-087508.md) | [(12.5) d](/filings/0001213900-25-107881.md) | [(17.0) d](/filings/0001213900-26-025433.md) | [(21.3)](/filings/0001213900-26-055463.md) | [(15.4) d](/filings/0001213900-26-087508.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001213900-24-096252.md) | [0.0 d](/filings/0001213900-25-020368.md) | not reported | not reported | [0.0 d](/filings/0001213900-25-107881.md) | [0.0 d](/filings/0001213900-26-025433.md) | [0.0](/filings/0001213900-26-055463.md) | [0.0 d](/filings/0001213900-26-087508.md) | [0.0 d](/filings/0001213900-25-107881.md) | [0.0 d](/filings/0001213900-26-025433.md) | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001213900-23-083013.md) | [0.0 d](/filings/0001213900-24-021982.md) | [0.1](/filings/0001213900-24-038757.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.3](/filings/0001213900-23-083013.md) | [11.3](/filings/0001213900-24-038757.md) | [11.3](/filings/0001213900-24-065380.md) | [11.3](/filings/0001213900-24-096252.md) | [11.4](/filings/0001213900-25-040811.md) | [21.2](/filings/0001213900-25-073942.md) | [22.3](/filings/0001213900-25-107881.md) | [40.7](/filings/0001213900-26-055463.md) | [42.3](/filings/0001213900-26-087508.md) | [42.3](/filings/0001213900-25-107881.md) | [57.5](/filings/0001213900-26-055463.md) | [61.0](/filings/0001213900-26-087508.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,095,488 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001213900-26-087508.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.